




Genmab A/S
Investor Relations Department
Kalvebod Brygge 43
1560 Copenhagen V
Denmark

[Visit IR website](#) 
[Sign-up for email alerts](#) 

OMX: GEN.OMX

| | |
|---------------|---|
| Last Trade: | 1241.00 |
| Trade Time: | 4:59 PM CET Feb 23, 2018 |
| Change: | 41.00  (3.417%) |
| Day Range | 1179.50 - 1241.00 |
| 52-Week Range | 994.80 - 1489.00 |
| Volume | 480,488 |

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Genmab A/S is listed on the NASDAQ Copenhagen A/S under the ticker symbol GEN and is traded as part of the OMXC25. Genmab is committed to proactive interaction with our shareholders and to provide reliable and transparent information about our business, development programs and results in an open and timely manner. In this area you can find information about Genmab's latest share price, our recent news flow and other relevant shareholder information related to our listing on Nasdaq.

... [\(more\)](#)

Press Releases [\[View all \]](#)

Feb 21, 2018

[Genmab 2017 Annual Report](#)

Jan 23, 2018

[Genmab Announces 2017 Net Sales Figures for DARZALEX® \(Daratumumab\)](#)

Jan 22, 2018

[Genmab Announces Novartis' Intention to Transition Arzerra® \(ofatumumab\) from Commercial Availability to Limited Availability via Compassionate Use Programs for the Treatment of CLL in Non-US Markets](#)

Jan 19, 2018

[U.S. FDA Grants Priority Review for Daratumumab in Front Line Multiple Myeloma](#)

Jan 9, 2018

[Major Shareholder Announcement](#)

Upcoming Events [\[View all \]](#)

Feb 26, 2018

[Deadline for shareholders to submit any items for consideration for the agenda of the Annual General Meeting in writing to the Board of Directors](#)

Feb 27, 2018

[Credit Suisse Healthcare Conference, London, UK](#)